Format

Send to

Choose Destination
Immunity. 2019 Jan 15;50(1):6-8. doi: 10.1016/j.immuni.2018.12.029.

The First Shall (Be) Last: Understanding Durable T Cell Responses in Immunotherapy.

Author information

1
Division of Molecular Oncology and Immunology, the Netherlands Cancer Institute, Oncode Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands. Electronic address: d.thommen@nki.nl.

Abstract

Efforts to understand how cancer immunotherapy restores anti-tumor T cell responses have largely concentrated on assessing the reactivation of dysfunctional T cells. In this issue of Immunity, Kurtulus et al. (2019) and Siddiqui et al. (2019) provide evidence that durable anti-tumor responses require less differentiated T cells that express the transcription factor Tcf1 and sustain the tumor-reactive T cell pool.

PMID:
30650381
DOI:
10.1016/j.immuni.2018.12.029
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center